IGC Pharma, Inc. IGC
AMEX
| 06/30/2026 | 03/31/2026 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 1.11M | 1.33M | 1.27M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 1.11M | 1.33M | 1.27M |
| Cost of Revenue | -- | -- | 595.00K | 717.00K | 652.00K |
| Gross Profit | -- | -- | 511.00K | 610.00K | 619.00K |
| SG&A Expenses | -- | -- | 4.36M | 4.00M | 4.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | 9.25M | 8.33M | 8.74M |
| Operating Income | -- | -- | -8.14M | -7.00M | -7.47M |
| Income Before Tax | -- | -- | -6.45M | -6.34M | -7.12M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -6.45 | -6.34 | -7.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -6.45M | -6.34M | -7.12M |
| EBIT | -- | -- | -8.14M | -7.00M | -7.47M |
| EBITDA | -- | -- | -7.57M | -6.41M | -6.85M |
| EPS Basic | -- | -- | -0.08 | -0.08 | -0.09 |
| Normalized Basic EPS | -- | -- | -0.05 | -0.05 | -0.06 |
| EPS Diluted | -- | -- | -0.08 | -0.08 | -0.09 |
| Normalized Diluted EPS | -- | -- | -0.05 | -0.05 | -0.06 |
| Average Basic Shares Outstanding | -- | -- | 330.70M | 316.25M | 306.04M |
| Average Diluted Shares Outstanding | -- | -- | 330.70M | 316.25M | 306.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |